Sparfloxacin and levofloxacin.
D000284:Administration, Oral; D000890:Anti-Infective Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001991:Bronchitis / Q000188:drug therapy; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D003875:Drug Eruptions / Q000209:etiology; D024841:Fluoroquinolones; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006801:Humans; D064704:Levofloxacin; D015242:Ofloxacin / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D010787:Photosensitivity Disorders / Q000139:chemically induced; D011014:Pneumonia / Q000188:drug therapy; D015363:Quinolones / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D015363:Quinolones; D064704:Levofloxacin; D015242:Ofloxacin; C061363:sparfloxacin